908 Devices Appoints Dr. Brandi Vann to Board, Expands Expertise in Nuclear, Chemical, and Biological Defense

908 Devices appoints Dr. Brandi Vann, former US Principal Deputy Assistant Secretary for Nuclear, Chemical, and Biological Defense, to its Board of Directors. Vann will provide strategic counsel as the company navigates opportunities in national security and global preparedness. Jeff George, a veteran biopharma leader, has stepped down from the Board due to the company's refocus on public health, safety, and defense tech.

908 Devices Inc. (Nasdaq: MASS), a pioneer in purpose-built handheld devices for chemical analysis, has appointed Dr. Brandi Vann to its Board of Directors. Dr. Vann brings extensive experience in nuclear, chemical, and biological defense programs, having served in several leadership positions at the U.S. Department of Defense (DoD). Her appointment follows the departure of Jeff George, a veteran biopharma leader, who stepped down due to the company's strategic refocus on public health, safety, and defense tech.

Dr. Vann, who previously held the position of Principal Deputy Assistant Secretary for Nuclear, Chemical, and Biological Defense at the DoD, will provide strategic counsel as 908 Devices navigates opportunities in national security and global preparedness. She has been a key advisor on nuclear weapons, nuclear energy, chemical and biological defense programs, and treaty management. Her tenure includes roles at the Defense Threat Reduction Agency (DTRA), where she led efforts in characterizing advanced and emerging chemical and biological threats.

"I’m thrilled to welcome Brandi to our Board of Directors. I’ve had the privilege of knowing her for many years, dating back to the founding of 908 Devices, and have always valued her insight," said Kevin J. Knopp, CEO and Co-founder, 908 Devices. "Her many years of leadership in CBRN detection enhance the strategic counsel of our board as we navigate opportunities in national security and global preparedness."

Dr. Vann expressed her excitement to join the 908 Devices Board of Directors, stating, "I’m honored to support its leadership team as they continue their mission to equip military personnel and first responders with field-ready devices that rapidly identify chemical threats."

The appointment of Dr. Vann aligns with 908 Devices' strategic focus on commercializing advanced chemical detection devices. Kevin Hrusovsky, chairman of 908 Devices, noted, "Brandi’s government experience and expertise in nuclear, chemical, and biological defense should be helpful as we shape and execute our strategy for commercializing advanced chemical detection devices. We also thank Jeff for his many contributions on our Board, including as chair of our compensation committee. He played an important role in helping shape our bioprocessing strategy and divestiture."

908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications such as the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The company's forward-looking statements, as outlined in its filings with the Securities and Exchange Commission, highlight the potential of its products and the challenges involved in commercializing advanced chemical detection devices.

References:
[1] https://www.stocktitan.net/news/MASS/908-devices-appoints-dr-brandi-vann-former-u-s-principal-deputy-0pkmscj7kuyk.html